Our R&D Institute in Paris-Saclay opens its doors to patients
Promoting access to the best possible care
for patients
We are committed to therapeutic progress to serve patient needs
We are committed to therapeutic progress to serve patient needs. We strongly believe that working with patients at all stages of the medicine’s life cycle leads to better care and solutions to support them throughout their journey.
As part of our efforts to uphold medicine quality and safety, we also combat counterfeit medicines, a serious problem that causes considerable disparities in access to treatment throughout the world.
We are committed to working for and with patients, day in, day out.
Empowering patients to work alongside us and play an active role in their own health
Patients are taking more and more control of their own health. At Servier, we see this shift as a unique opportunity to work both with and for them to develop medicines that better suit their needs.
We involve them in our work, right from the moment the molecule design process begins and at every stage of the medicine life cycle.
Their understanding of their illnesses and the medicines they take drive our research, which in turn improves treatment and increases the effectiveness of the therapeutic solutions we develop.
We particularly appreciate the valuable contribution made by patient organizations, from diagnosis through to properly following treatment.
Genuine therapeutic progress comes through close collaboration with patients.
2nd
Ranked 2nd out of 23 companies by oncology patient organizations, according to the PatientView Report 2022 on the reputation of pharmaceutical companies (up five places from the previous year)
12
international or European patient organizations collaborated with Servier in 2023
66%
of informed consent forms filled out by people taking part in Servier Group clinical trials were reviewed by patients in 2022-2023. We aim to reach 100% within the next three years.
100%
of our lay summaries are approved by patient representative bodies and translated into the language of every country involved in the study.
65%
of clinical research projects were reviewed by patients in 2022-2023.
Harnessing industrial excellence and independence to benefit patients
Au sein de nos 16 sites de production répartis à travers le monde, nous fabriquons des médicaments conformément aux plus hauts standards de qualité, de sécurité et de fiabilité.
Thanks to our network of 16 production sites located throughout the world, we produce and distribute our medicines in accordance with the highest standards on quality, safety and reliability.
As a pharmaceutical Group deeply committed to health independence, we have always actively chosen to maintain significant production capacity in Europe. That is why we produce 96.5% of our active ingredients at our Oril Industrie facility in France, before distributing them to nine production sites for use in medicines prescribed in cardiology, neuroscience and diabetes.
Security and quality guarantee
96,5%
of our active ingredients are produced at our Oril Industrie facility in France.
By harnessing digital innovation across the entire value chain, we continue to enhance our ability to meet patient demand.
Furthering medication adherence
The WHO estimates that if everyone diagnosed with a chronic disease followed their treatment plan to the letter, 12,000 deaths in France and 200,000 in Europe could be avoided. It is therefore one of our priorities to further medication adherence among patients.
We invest in three key areas:
In 2023, the World Health Organization included one of our Single Pill Combinations used to treat several cardiovascular diseases in its Model List of Essential Medicines for the first time.
Elfie, an app to manage chronic diseases: we joined forces with the Singapore-based start-up Elfie, which has developed a free and fun app boasting a number of features to improve medication adherence, including blood pressure tracking, reminders to take medicine, step and weight tracking and a digital pill box.
Over the past five years, we have been collaborating with patient organizations to develop information campaign about hypertension (Because I say so) and diabetes (Act now for diabetes).
Combating counterfeit medicine
Counterfeit medicines represent a serious risk to public health and a danger to patients, as there can be a lack of active ingredients, incorrect dosage, impurities and toxic substances.
The WHO estimates that 10% of medicines distributed in developing countries are of substandard quality or are counterfeit. Counterfeit medicine therefore represents a major cause of inequalities in treatment.
We have been working for several decades to counter the scourge of counterfeit medicines.
As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), we promote prevention, training and medicine traceability.
In addition, our specialist teams are involved in developing innovative technology, such as electronic and near infrared product labeling which serve to analyze suspicious boxes of medicines found throughout the world. More generally, our generic medicines help combat the problem posed by falsified medicines; as generics are less expensive than brand-name medicines, they help drive counterfeit drugs off the market.
As a member of the Anti-Counterfeit Group within the European Federation of Pharmaceutical Industries and Associations, we take steps to enhance prevention, training and medicine traceability.
We have put together a dedicated team to combat counterfeit medicine, based in France and China.
We take steps to improve medicine traceability, for example by printing unique serial numbers on boxes as well as measures to guarantee security and authenticity. We also provide authorities with training and organize awareness campaigns to combat counterfeit medicines.
The Group manufactures over 1,500 generic medicines covering the majority of illnesses. As generics are less expensive than brand-name medicines, they help drive counterfeit drugs off the market.
“Patient’s Side of the Story”: Involving patients in medical research
Gaining perspective on therapeutic adherence through a Servier study in cardiology
Should you have any doubts or questions
A single link to report any suspicions